Integrating Bulk-seq and Single-cell-seq Reveals Disulfidptosis Potential Index Associating with Neuroblastoma Prognosis and Immune Infiltration

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Sep 18

PMID 37721569

Authors

Aiguo Zhu

Xin Li

Jian Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Neuroblastoma is a challenging pediatric tumor with a need for improved treatment strategies. This study explores the role of disulfidptosis, a form of cell death induced by intracellular disulfide accumulation, in neuroblastoma and its implications for prognosis and immune infiltration.

Methods: We subgrouped neuroblastoma samples based on disulfidptosis-related gene expression and constructed a disulfidptosis potential index (DPI) to quantify disulfidptosis levels in neurobalstoma. The correlation between DPI, outcome, immune infiltration, and drug sensitivity were explored.

Results: Combing RNA-seq and single-cell dataset, we found that higher disulfidptosis potential index (DPI) is associated with poorer outcomes in neuroblastoma patients, indicating the detrimental impact of enhanced disulfide stress and cellular dysfunction. Furthermore, we found that higher DPI is correlated with reduced immune infiltration within the tumor microenvironment, highlighting an immunosuppressive milieu in high DPI neuroblastomas. The DPI-high neuroblastoma may benefit from the estrogen pathway related drug fulvestrant.

Conclusion: Overall, this study highlights the significance of disulfidptosis as a potential therapeutic target and underscores the importance of integrating immune modulation strategies, offering new avenues for improved management of neuroblastoma.

Citing Articles

Construction of a disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immunotherapy in neuroblastoma.

Fu Y, Zhang N, Wang J, Wang Y, Zhang D Transl Cancer Res. 2024; 13(11):5909-5928.

PMID: 39697700 PMC: 11651765. DOI: 10.21037/tcr-24-510.

Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma.

Mengzhen Z, Xinwei H, Zeheng T, Nan L, Yang Y, Huirong Y J Cancer Res Clin Oncol. 2024; 150(3):109.

PMID: 38427078 PMC: 10907485. DOI: 10.1007/s00432-024-05630-8.

References

Almstedt E, Elgendy R, Hekmati N, Rosen E, Warn C, Olsen T . Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun. 2020; 11(1):71. PMC: 6941971. DOI: 10.1038/s41467-019-13817-8. View

Anderson J, Majzner R, Sondel P . Immunotherapy of Neuroblastoma: Facts and Hopes. Clin Cancer Res. 2022; 28(15):3196-3206. PMC: 9344822. DOI: 10.1158/1078-0432.CCR-21-1356. View

Armideo E, Callahan C, Madonia L . Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications. J Adv Pract Oncol. 2018; 8(1):44-55. PMC: 5995538. DOI: 10.6004/jadpro.2017.8.1.4. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

Crunkhorn S . Understanding PI3K inhibitor mechanism of action. Nat Rev Drug Discov. 2021; 20(11):816. DOI: 10.1038/d41573-021-00173-w. View

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K . The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019; 18(1):100. PMC: 6532150. DOI: 10.1186/s12943-019-1029-8. View

Ham J, Costa C, Sano R, Lochmann T, Sennott E, Patel N . Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 2016; 29(2):159-72. PMC: 4749542. DOI: 10.1016/j.ccell.2016.01.002. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

10.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

11.

Kitanaka C, Kato K, Ijiri R, Sakurada K, Tomiyama A, Noguchi K . Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst. 2002; 94(5):358-68. DOI: 10.1093/jnci/94.5.358. View

12.

Li Y, Nakagawara A . Apoptotic cell death in neuroblastoma. Cells. 2014; 2(2):432-59. PMC: 3972687. DOI: 10.3390/cells2020432. View

13.

Li W, Li X, Xia Y, Wang J . Pyroptosis-Related Gene Signature Predicts the Prognosis and Immune Infiltration in Neuroblastoma. Front Genet. 2022; 13:809587. PMC: 9162481. DOI: 10.3389/fgene.2022.809587. View

14.

Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M . Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023; 25(3):404-414. PMC: 10027392. DOI: 10.1038/s41556-023-01091-2. View

15.

Machesky L . Deadly actin collapse by disulfidptosis. Nat Cell Biol. 2023; 25(3):375-376. DOI: 10.1038/s41556-023-01100-4. View

16.

Morgenstern D, Bagatell R, Cohn S, Hogarty M, Maris J, Moreno L . The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2018; 66(4):e27556. DOI: 10.1002/pbc.27556. View

17.

Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschella G . Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 2015; 6:e2010. PMC: 4720889. DOI: 10.1038/cddis.2015.354. View

18.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

19.

Schubert M, Klinger B, Klunemann M, Sieber A, Uhlitz F, Sauer S . Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018; 9(1):20. PMC: 5750219. DOI: 10.1038/s41467-017-02391-6. View

20.

Smith V, Foster J . High-Risk Neuroblastoma Treatment Review. Children (Basel). 2018; 5(9). PMC: 6162495. DOI: 10.3390/children5090114. View